Name:
"Blautia massiliensis" Durand et al. 2017
DSM No.:
101187, Proposed type strain
Strain designation:
GD9, CSUR P2132
Other collection no.
or WDCM no.:
GD9,CSUR P2132
Isolated from:
stool specimen of a healthy patient
Country:
France
Marseille, La Timone hospital
Date of sampling:
2015
Nagoya Protocol Restrictions:
France requires a benefit-sharing declaration for French genetic resources at the time of utilization, i.e., conducting research. France considers access to genetic resources when utilization begins and not when the initial collection of the material took place and applies to material both in-situ and ex-situ and users within and outside of France.
To comply with French law, you, the user need to make a Declaration regarding access to genetic resources and benefit-sharing arising from your non-commercial utilisation of genetic resources. The steps are the following:
1. File a declaration via the CERFA form n. 15786 (https://www.formulaires.service-public.fr/gf/getAnnexe.do?cerfaAnnexe=1&cerfaFormulaire=15786*02) or by electronic procedure (https://www.demarches-simplifiees.fr/commencer/apa-declaration-pmorale)
2. Await approval by the Ministry for the Ecological Transition, the competent national authority
3. Respond to any requests for more information from the competent national authority
4. Receive an acknowledgment of receipt by the competent national authority certifying the prior informed consent (PIC) and establishment of mutually agreed terms (MAT) regarding benefit-sharing. This procedure shall not exceed 2 months.
For more information about this topic please see the Access and Benefit-Sharing Clearing House: https://absch.cbd.int/en/countries/FR
For more information about the commercial use of this genetic resources please contact: justiziariat@dsmz.de
History:
<- S. Khelaifia, Timone Hospital, Marseille, France; GD9 <- Unité de Recherche sur les Maladies Infectieuses et Tropicales Émergentes
Genbank accession numbers:
whole genome shotgun sequence: FAVI00000000
